Semaglutide tablet (Rybelsus), the first GLP-1RA developed for oral administration, heralds a milestone for diabetes management in the 15 years since the introduction of the first glucagon-like peptide-1 receptor agonist (GLP-1RA). Rybelsus and its parenteral counterpart, Semaglutide (Ozempic), are approved for use in the treatment of . . .
Pancreatic cancer is the 12th most commonly found cancer globally, affecting men more than women.